We Are One Seven LLC lifted its position in shares of Steris PLC (NYSE:STE) by 2.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,545 shares of the medical equipment provider’s stock after buying an additional 157 shares during the period. We Are One Seven LLC’s holdings in Steris were worth $1,123,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Fort L.P. boosted its position in shares of Steris by 23.6% during the first quarter. Fort L.P. now owns 19,561 shares of the medical equipment provider’s stock worth $2,504,000 after buying an additional 3,733 shares during the period. Amundi Pioneer Asset Management Inc. raised its stake in Steris by 6.9% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 65,660 shares of the medical equipment provider’s stock valued at $7,016,000 after buying an additional 4,229 shares during the period. Neuburgh Advisers LLC raised its stake in Steris by 22.5% in the first quarter. Neuburgh Advisers LLC now owns 11,748 shares of the medical equipment provider’s stock valued at $1,505,000 after buying an additional 2,156 shares during the period. Texas Permanent School Fund raised its stake in Steris by 3.9% in the first quarter. Texas Permanent School Fund now owns 57,433 shares of the medical equipment provider’s stock valued at $7,353,000 after buying an additional 2,137 shares during the period. Finally, Twin Capital Management Inc. raised its stake in Steris by 0.6% in the first quarter. Twin Capital Management Inc. now owns 34,440 shares of the medical equipment provider’s stock valued at $4,409,000 after buying an additional 200 shares during the period. 83.98% of the stock is owned by institutional investors.
A number of brokerages have recently weighed in on STE. Stephens reiterated a “hold” rating and set a $17.00 target price on shares of Capstar Financial in a research note on Wednesday, May 15th. JMP Securities increased their target price on Steris from $135.00 to $150.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 22nd. Zacks Investment Research lowered German American Bancorp. from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. Finally, KeyCorp increased their target price on Steris from $135.00 to $138.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 15th. Five analysts have rated the stock with a buy rating, Steris has a consensus rating of “Buy” and a consensus price target of $148.20.
Steris (NYSE:STE) last released its quarterly earnings data on Monday, May 13th. The medical equipment provider reported $1.53 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.44 by $0.09. Steris had a return on equity of 13.34% and a net margin of 10.93%. The company had revenue of $768.00 million for the quarter, compared to the consensus estimate of $738.87 million. During the same quarter last year, the business posted $1.24 EPS. Steris’s revenue for the quarter was up 7.3% on a year-over-year basis. On average, equities research analysts forecast that Steris PLC will post 5.37 EPS for the current year.
In related news, VP Karen L. Burton sold 1,387 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $133.89, for a total transaction of $185,705.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Walter M. Rosebrough, Jr. sold 119,000 shares of the firm’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $132.56, for a total value of $15,774,640.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 244,145 shares of company stock worth $33,121,338. 2.36% of the stock is currently owned by company insiders.
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Read More: Percentage Gainers
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.